ZeZentalis Pharma
ZNTL4.5104.16% ( +0.180 )
ZeZentalis Pharma (ZNTL)
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment...
- Open
- 4.360
- High
- 4.650
- Low
- 4.350
- Prev. Close
- 4.330
- Volume
- 1.03M
- Turnover
- 4.68M
- Avg Price
- 4.548
- Bid/Ask Ratio
- --
- Amplitude
- 6.93%
- 52wk High
- 6.950
- Volume Ratio
- 0.68
- Turnover Ratio
- 2.12%
ZeZentalis Pharma Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$6.6747.82%
Forecast & RatingBuy
10analysts
- Strong buy50.00%
- Buy0.00%
- Hold50.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 23 at 07:06 AM
Rodman & Renshaw Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)
- Global Report · Jul 19 at 04:13 AM
Cross-Currents in US Equities: From AI Integration Triumphs to Crypto Casualties
- benzinga_article · Jul 17 at 09:09 AM
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
- StockTitan · Jul 17 at 07:15 AM
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 | ZNTL Stock News
- Tip Ranks · Jul 17 at 03:55 AM
Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL)
- StockTitan · Jun 1 at 08:00 AM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News
